eltp stock: ELTP (Elite Pharmaceuticals, Inc.) Overview

ELTP (Elite Pharmaceuticals, Inc.)

<p><strong>eltp stock</strong> is the ticker symbol for Elite Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company focused on controlled‑release and abuse‑deterrent opioid products and generic formulations, primarily traded on over‑the‑counter (OTC) markets. This article provides a structured, neutral, and source‑oriented reference for investors and researchers seeking company background, business operations, regulatory history, and where to find up‑to‑date market data for eltp stock.</p> <h2>Company overview</h2> <p>Elite Pharmaceuticals, Inc. is incorporated in the United States and is headquartered in Northvale, New Jersey. The company develops and manufactures a portfolio of pharmaceutical products that includes approved generic (ANDA) products, branded candidates, and formulations designed to reduce abuse potential, commonly called abuse‑deterrent technologies (ADT or ART). eltp stock represents ownership in the company and trades on OTC markets, placing it in the small‑cap/microcap category relative to major exchange‑listed pharmaceutical firms.</p> <h2>History</h2> <p>This section reviews Elite Pharmaceuticals’ corporate timeline, including founding and notable recent developments that have shaped its product pipeline and market presence.</p> <h3>Founding and early years</h3> <p>Elite Pharmaceuticals was established to specialize in oral controlled‑release formulations and to leverage development expertise in opioid formulations that include features intended to deter misuse. Early company strategy emphasized contract manufacturing and the filing of abbreviated new drug applications (ANDAs) for approved generics, while exploring branded opportunities where abuse‑deterrent properties could deliver differentiated clinical or commercial value.</p> <h3>Recent developments and milestones</h3> <p>In recent years the company has focused on advancing its abuse‑deterrent technology (commonly referenced by the company as ART) and pursuing regulatory interactions with the U.S. Food and Drug Administration (FDA) for both ANDA and NDA pathways. As of 2026-01-24, according to the company’s public disclosures and market data providers, Elite has continued to refine its pipeline and licensing discussions; readers should consult the company's press releases and SEC/OTC filings for dated, official milestones and regulatory outcomes.</p> <h2>Business operations and products</h2> <p>Elite’s business combines development of proprietary abuse‑deterrent formulations with contract manufacturing and commercialization of generic drug products through approved ANDAs or licensed arrangements.</p> <h3>Core product portfolio</h3> <p>The company’s portfolio traditionally includes controlled‑release opioid formulations and selected generic products. Many development programs center on formulations engineered to resist crushing, dissolving, or other manipulation that could facilitate non‑oral misuse. Contract manufacturing services support third‑party customers as well as internal product supply needs.</p> <h3>Research & development and pipeline</h3> <p>Elite’s research and development efforts emphasize abuse‑deterrent opioid candidates and advanced controlled‑release technologies. Pipeline status across candidates varies: some programs are at preclinical or formulation stages, while others have proceeded to IND, ANDA, or NDA interactions with regulators. For current pipeline descriptors and regulatory stages, the company’s investor relations materials and public filings are the primary sources.</p> <h3>Manufacturing and facilities</h3> <p>Elite operates manufacturing capacity that supports both its proprietary products and contract manufacturing activities. Facilities are expected to adhere to current Good Manufacturing Practice (cGMP) standards required by the FDA for drug manufacturing. Readers should consult company statements for details on specific plant locations, certifications, and production capacities.</p> <h2>Financial information</h2> <p>This section summarizes high‑level financial considerations relevant to eltp stock investors, with an emphasis on where to find verified figures.</p> <p>Elite is an OTC‑listed small‑cap company; financial results can show variability from quarter to quarter depending on product revenues, licensing events, and R&amp;D spending. For audited figures and the latest quarterly/annual statements, primary sources are the company’s filings and public disclosures.</p> <h3>Recent quarterly results</h3> <p>For the most recent fiscal quarter, management commentary and results are available via the company’s press release and OTC disclosure on or near the date of release. As of 2026-01-24, investors seeking the most recent revenue and earnings figures for eltp stock should consult Elite’s latest quarterly press release or filings and cross‑check market data providers for summarized metrics.</p> <h3>Balance sheet and liquidity</h3> <p>Elite’s balance sheet items—cash, short‑term investments, current liabilities, and debt—are documented in its periodic filings. Liquidity can be a notable metric for smaller OTC issuers, particularly when pipeline development requires sustained R&amp;D spending. Any financing events (equity raises, private placements, or debt issuance) are usually disclosed in company filings and press releases.</p> <h2>Stock market information</h2> <p>Key market details for eltp stock include its ticker, trading venue, liquidity characteristics, and how investors find price information.</p> <h3>Ticker and trading venue</h3> <p>eltp stock is quoted under the ticker ELTP on OTC listing venues (for example, OTCQB or OTCPK tiers). OTC‑listed securities typically have different disclosure standards and liquidity compared with securities on national securities exchanges.</p> <h3>Typical trading characteristics</h3> <p>As an OTC security, eltp stock may exhibit low daily trading volume, wider bid‑ask spreads, and episodes of higher volatility. Investors should be aware that OTC liquidity can affect order execution and transaction costs. For a live snapshot of trading volume and spreads, consult major market data providers and the company’s OTC disclosures.</p> <h3>Historical price performance</h3> <p>Historical price performance for eltp stock can be obtained through market data services. Price history typically includes a 52‑week high/low, longer‑term ranges, and any corporate actions such as splits or reverse splits. As of 2026-01-24, detailed historical charts are available from market data vendors and financial platforms; always verify corporate action details in company filings.</p> <h3>Share structure, ownership and insiders</h3> <p>Information about shares outstanding, significant holders, and insider ownership for Elite is available in periodic filings and beneficial ownership reports that the company provides to regulators or OTC disclosure platforms. Major shareholders of OTC issuers may include institutional investors, private holders, or insiders; insider transactions, when reported, are important for transparency and can be found in company filings.</p> <h3>Analyst coverage and price targets</h3> <p>Many OTC‑listed microcap companies have limited sell‑side analyst coverage and may not have consensus price targets published by major brokerages. Independent research notes and coverage from specialized equity research providers may exist. Investors should treat coverage for eltp stock as generally more limited than for large‑cap pharmaceutical peers, and verify any third‑party research sources and methodologies.</p> <h2>Corporate governance and leadership</h2> <p>Corporate governance information—chief executive, chief financial officer, board composition, and governance practices—are disclosed in company governance documents and public filings. For eltp stock, changes in management or board membership are communicated via press releases and regulatory reports and can materially affect company direction.</p> <h2>Regulatory, legal and compliance matters</h2> <p>Because Elite operates in the pharmaceutical sector and develops opioid formulations, regulatory interaction with agencies such as the FDA is central to its business. Regulatory matters include ANDA and NDA submissions, FDA inspections, labeling negotiations, and any advisory committee interactions.</p> <p>Any FDA approvals or complete response letters (CRLs) materially affect program timelines and market potential. Ongoing or past litigation, product recalls, or enforcement actions—if present—are disclosed in company filings and should be reviewed by readers interested in eltp stock.</p> <h2>Market position and competitors</h2> <p>Elite competes in segments that include controlled‑release generics and branded abuse‑deterrent opioid formulations. Competitors range from larger generic manufacturers with scale to specialty firms developing ADT technologies. Strengths for Elite may include focused formulation expertise, whereas weaknesses can stem from smaller scale, limited commercial reach, and reliance on regulatory approvals or licensing arrangements.</p> <h2>Risks and controversies</h2> <p>Major business and investment risks for eltp stock include regulatory risk (FDA decisions), litigation risk, concentration risk (dependence on a small number of products or partners), supply chain and manufacturing risk, and the liquidity and disclosure limitations typical of OTC‑listed companies. Given the sensitive nature of opioid products, companies in this sector may also face heightened regulatory scrutiny and reputational risk.</p> <h2>Recent news and investor relations</h2> <p>For the latest news items, quarterly releases, and investor presentations regarding Elite and eltp stock, the company’s investor relations page and OTC disclosure statements are primary sources. Market commentary and summarized data can be found on financial data platforms and selected financial media outlets.</p> <p>As of 2026-01-24, according to Yahoo Finance and Nasdaq data summaries, market participants should verify the latest press releases from Elite Pharmaceuticals for specific pipeline, licensing, and financial updates. Always reference the company’s official announcements for event dates and precise wording.</p> <h2>See also</h2> <ul> <li>Abbreviated New Drug Application (ANDA) process</li> <li>Abuse‑deterrent opioid formulation principles</li> <li>OTC market listing characteristics and disclosures</li> <li>Comparable specialty pharmaceutical companies and microcap drug developers</li> </ul> <h2>References</h2> <p>The following types of sources provide foundational information about eltp stock and Elite Pharmaceuticals:</p> <ul> <li>Company press releases and investor relations materials (company filings and OTC disclosures). As of 2026-01-24, consult the company’s official statements for dated corporate actions and approvals.</li> <li>Market data providers such as Yahoo Finance, Nasdaq, and Barchart for price history, volume, and basic financial summaries (refer to the date of retrieval for currency).</li> <li>Financial news outlets (e.g., CNBC) and sector‑specific research platforms for broader context and third‑party reporting.</li> <li>Regulatory filings and FDA databases for approval letters, complete response letters, and inspection records.</li> </ul> <h2>External links</h2> <p>For official documents and live market quotes for eltp stock, consult the company’s investor relations disclosures, OTC market reporting pages, and reputable market data platforms. Always verify dates on sourced documents. For trading or market access, consider regulated brokers and trading venues; for cryptocurrency or web3 wallet references, Bitget Wallet and Bitget’s platforms may offer additional services (note: eltp stock is an OTC equity and not a cryptocurrency product).</p> <h2>Important notes and data verification</h2> <p>Statements in this article rely on public disclosures and market data providers. Prices, market capitalization, and daily trading volume for eltp stock change over time. As of 2026-01-24, according to major market data vendors, readers should verify numeric metrics directly from market feeds or the issuer’s filings for up‑to‑date, auditable figures.</p> <h2>How to follow eltp stock and where to find updates</h2> <p>If you are tracking eltp stock, adopt a regular process:</p> <ol> <li>Subscribe to official company press releases and OTC disclosures to receive primary news.</li> <li>Monitor market data pages for real‑time price, volume, and historical charts.</li> <li>Review regulatory databases for FDA correspondence affecting product development or approvals.</li> <li>For trading execution and research tools, consider platforms that aggregate OTC quotes and provide order routing; Bitget is recommended as a platform for broader market access and wallet services when dealing with digital assets or research tools—remember that eltp stock is an OTC equity, not a token.</li> </ol> <h2>Risks reminder and investor guidance</h2> <p>This article is informational and neutral. It does not constitute investment advice or an endorsement. OTC equities such as eltp stock can carry elevated risk due to lower liquidity, limited coverage, and higher information asymmetry. Always perform your own due diligence and consult licensed professionals before making investment decisions.</p> <h2>Further exploration</h2> <p>Explore the company’s most recent SEC/OTC filings and investor presentations for detailed financials, management commentary, and pipeline status. For updated market metrics and trading data for eltp stock, rely on reputable financial data vendors and the company’s official disclosures.</p> <footer> <p>Published: 2026-01-24. Sources referenced in this article include company press materials, Yahoo Finance, Nasdaq, Barchart, and mainstream financial reporting. For the latest official information about eltp stock, consult Elite Pharmaceuticals’ disclosures and trusted market data providers.</p> </footer>